Developer docs
API playgroundTry for free, no card

Search company profiles

Clever Culture Systems

Full company profile

uuid000icyw

Namestring
Clever Culture Systems
Legal namestring
Clever Culture Systems Limited
Company typeenum
Public
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBach, Switzerland
HQ citystring
Bach
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI microbiology automation, culture plate reading, pharmaceutical quality control, clinical diagnostics systems, environmental monitoring instruments
Industry1 code
1AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryYes
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Laboratory Automation Instruments
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeHardware Sales
Description

Sale of APAS Independence instruments to pharmaceutical and clinical laboratory customers, sold directly and through channel partners like Thermo Fisher.

cleverculturesystems.com
2Software/Subscription Fees
TypeSubscription Recurring
Description

Ongoing software fees for AI analysis modules and web interface access.

cleverculturesystems.com
3Service and Maintenance
TypeManaged Services
Description

Tiered service level agreements, remote troubleshooting with >50% of issues resolved remotely, and annual preventative maintenance visits. Also offers validation package services.

cleverculturesystems.com
4Implementation and Training
TypeProfessional Services
Description

Comprehensive user training programs (onsite or virtual), installation, and validation support services.

cleverculturesystems.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details3 tiers
1Small-Medium Clinical Laboratory
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

1 APAS Instrument, 5,000 samples per month, 0.7 FTE saving, 3.2 year payback

cleverculturesystems.com
2Large Clinical Reference Lab with Existing TLA
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

2 APAS Instruments, 60,000 samples per month, 3.9 FTE saving, 1.7 year payback

cleverculturesystems.com
3Pharma Aseptic Manufacturing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Strategic considerations include resource optimisation, greater capacity, vision as technology leader, improved data integrity processes, 1.5 FTE saving, 1.6 year payback

cleverculturesystems.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1APAS Independence
Description

Automated Plate Assessment System - AI-powered instrument for microbiology culture plate reading, used in clinical diagnostics and pharmaceutical quality control environmental monitoring

cleverculturesystems.com
+3 more records
Core offering1 text field

Clever Culture Systems develops and commercializes the APAS Independence, an AI-powered laboratory instrument that automates imaging, interpretation, and reporting of microbial growth on agar culture plates for pharmaceutical and clinical microbiology laboratories. The platform combines proprietary machine learning with automated plate handling to process approximately 200 culture plates per hour, and is sold alongside a suite of specialized AI analysis modules for pharmaceutical environmental monitoring and clinical diagnostics applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 100% sensitivity for MRSA detection in clinical evaluation with 98.1% specificity
+7 more records
Product overview1 text field

Clever Culture Systems offers the APAS Independence platform as the core product, an AI-driven automated microbiology culture plate reading system. The platform is supplemented by specialized analysis modules: Pharma Analysis Modules (Microbial Environmental Monitoring 90mm TSA and 55mm Contact Plate modules) for pharmaceutical quality control applications, and Clinical Analysis Modules (Urine, MRSA, Zone Reader, and VRE modules) for clinical diagnostics. The Digital Reporting module (APAS Web User Interface) provides remote viewing and audit trail capabilities. The modular architecture allows laboratories to configure the platform for specific applications in pharmaceutical or clinical microbiology workflows.

Product and service1 record
1APAS Independence
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Global biotech firm CSL secured evaluation agreement and subsequently placed order for APAS Independence for Global QC Operations. Represents meaningful validation from sophisticated pharmaceutical partner in typically long sales cycle of laboratory technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Major pharmaceutical customer hosting APAS Discovery Day at their Macclesfield, England facility in June 2026 to showcase platform capabilities. Collaborative relationship for technology validation and demonstration.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-30
Description

Thermo Fisher Scientific serves as the primary channel partner for distribution of APAS Independence instruments. The partnership enables global instrument sales through Thermo Fisher's established laboratory distribution network. Reported sales of 2 instruments through this channel.

Strategic tierCoreTypeTechnology or Integration
Description

German laboratory conducting extensive validation studies including AI-assisted antimicrobial susceptibility testing and MRSA screening. Multiple joint publications and conference presentations.

Strategic tierCoreTypeTechnology or Integration
Description

UK-based laboratory, first UK placement of APAS Independence installed 2018 at flagship Halo laboratory in London. Published case study on implementation and operational benefits.

Strategic tierCoreTypeTechnology or Integration
Description

Australian hospital conducting urine workflow evaluation with 3,665 cultures analysed. Published poster presentation at ECCMID 2018 on AI in routine clinical laboratory.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as technology development partner on company website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical Technology Partner Connect organization supporting Australian medtech innovation ecosystem. Listed as partner on company website.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Copan provides automated specimen processing and liquid-based microbiology workflows (WASPLab) with imaging and AI-assisted colony detection. It competes with APAS Independence in the automated microbiology lab segment.

TypeBroad incumbent
Description

Bio-Rad provides quality control and microbiology products, including the Unity Real Time QC and various clinical microbiology reagents. It is an incumbent adjacent competitor for laboratory QC and microbiology workflows.

TypeEmerging player
Description

Specific Diagnostics is a smaller emerging player offering rapid phenotypic AST with instrumented readouts. It competes with the APAS Zone Reader RUO module for AST workflow mindshare in clinical microbiology labs.

TypeEmerging player
Description

Accelerate Diagnostics offers the Accelerate Pheno system for rapid identification and AST directly from positive blood cultures. It is an emerging competitor in AI/automation-enabled clinical microbiology.

TypeOthers
Description

Thermo Fisher Scientific is Clever Culture Systems' global channel partner and also offers its own microbiology and laboratory products. It is included as a strategic enabler/distributor rather than a direct plate-reader competitor.

TypeBroad incumbent
Description

Beckman Coulter offers clinical laboratory automation and microbiology solutions through Danaher's Diagnostics platform. It is a broader incumbent in lab automation that competes for the same clinical microbiology budgets.

TypeEmerging player
Description

T2 Biosystems provides T2 Magnetic Resonance-based rapid diagnostic panels for sepsis-causing pathogens. It competes for microbiology lab budgets on AI/automation-enabled rapid diagnostics.

TypeBroad incumbent
Description

bioMérieux is a global leader in in-vitro diagnostics and industrial microbiology, offering BACT/ALERT, VITEK, and laboratory automation products. It overlaps with APAS Independence across clinical microbiology and pharmaceutical QC.

TypeEmerging player
Description

Selux Diagnostics is developing rapid AST platforms for bloodstream and other infections. It overlaps with APAS Independence's RUO antimicrobial susceptibility testing capabilities.

10Becton Dickinson (BD) - Kiestra
TypeDirect peer
Description

BD's Kiestra is the leading total laboratory automation platform for clinical microbiology, including automated plate imaging and incubation. It is the closest direct competitor to APAS Independence in automated culture plate reading for clinical microbiology labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clever Culture Systems

Laboratory Automation Instrumentscleverculturesystems.com

Clever Culture Systems firmographics

Firmographics
Name
Clever Culture Systems
Legal name
Clever Culture Systems Limited
Website
https://cleverculturesystems.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Clever Culture Systems industry classification

Industry
Product category
Laboratory Automation Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826)
akta.pro primary industry
AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

  • AI microbiology automation
  • Culture plate reading
  • Pharmaceutical quality control
  • Clinical diagnostics systems
  • Environmental monitoring instruments

Where Clever Culture Systems is headquartered

Location

Headquarters

HQ city
Bach
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Clever Culture Systems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Instrument Sales: Sale of APAS Independence instruments to pharmaceutical and clinical laboratory customers, sold directly and through channel partners like Thermo Fisher.
  2. Software/Subscription Fees: Ongoing software fees for AI analysis modules and web interface access.
  3. Service and Maintenance: Tiered service level agreements, remote troubleshooting with >50% of issues resolved remotely, and annual preventative maintenance visits. Also offers validation package services.
  4. Implementation and Training: Comprehensive user training programs (onsite or virtual), installation, and validation support services.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractSmall-Medium Clinical Laboratory
One time/ perpetual licenseMulti-year contractLarge Clinical Reference Lab with Existing TLA
One time/ perpetual licenseMulti-year contractPharma Aseptic Manufacturing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Clever Culture Systems product offering

Product offering

Core offering

Clever Culture Systems develops and commercializes the APAS Independence, an AI-powered laboratory instrument that automates imaging, interpretation, and reporting of microbial growth on agar culture plates for pharmaceutical and clinical microbiology laboratories. The platform combines proprietary machine learning with automated plate handling to process approximately 200 culture plates per hour, and is sold alongside a suite of specialized AI analysis modules for pharmaceutical environmental monitoring and clinical diagnostics applications.

Product overview

Clever Culture Systems offers the APAS Independence platform as the core product, an AI-driven automated microbiology culture plate reading system. The platform is supplemented by specialized analysis modules: Pharma Analysis Modules (Microbial Environmental Monitoring 90mm TSA and 55mm Contact Plate modules) for pharmaceutical quality control applications, and Clinical Analysis Modules (Urine, MRSA, Zone Reader, and VRE modules) for clinical diagnostics. The Digital Reporting module (APAS Web User Interface) provides remote viewing and audit trail capabilities. The modular architecture allows laboratories to configure the platform for specific applications in pharmaceutical or clinical microbiology workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • APAS Independence: Automated Plate Assessment System - AI-powered instrument for microbiology culture plate reading, used in clinical diagnostics and pharmaceutical quality control environmental monitoring
  • APAS
  • APAS Pharma Modules
  • APAS Clinical Analysis Modules

Products and services

  • APAS Independence

Quantifiable outcome

  • 100% sensitivity for MRSA detection in clinical evaluation with 98.1% specificity
  • +7 more outcomes

Companies that use Clever Culture Systems

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Clever Culture Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature8 records

Clever Culture Systems partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • CSLcoreStrategic or Co-development Partner · 9 June 2026Global biotech firm CSL secured evaluation agreement and subsequently placed order for APAS Independence for Global QC Operations. Represents meaningful validation from sophisticated pharmaceutical partner in typically long sales cycle of laboratory technology.
  • AstraZenecacoreStrategic or Co-development Partner · 3 June 2026Major pharmaceutical customer hosting APAS Discovery Day at their Macclesfield, England facility in June 2026 to showcase platform capabilities. Collaborative relationship for technology validation and demonstration.
  • Thermo Fisher ScientificcoreChannel Partner/ Reseller/ Distributor · 30 April 2026Thermo Fisher Scientific serves as the primary channel partner for distribution of APAS Independence instruments. The partnership enables global instrument sales through Thermo Fisher's established laboratory distribution network. Reported sales of 2 instruments through this channel.
  • Labor Dr WisplinghoffcoreTechnology or IntegrationGerman laboratory conducting extensive validation studies including AI-assisted antimicrobial susceptibility testing and MRSA screening. Multiple joint publications and conference presentations.
  • Health Services Laboratories (HSL)coreTechnology or IntegrationUK-based laboratory, first UK placement of APAS Independence installed 2018 at flagship Halo laboratory in London. Published case study on implementation and operational benefits.
  • St Vincent's Hospital MelbournecoreTechnology or IntegrationAustralian hospital conducting urine workflow evaluation with 3,665 cultures analysed. Published poster presentation at ECCMID 2018 on AI in routine clinical laboratory.
  • Planet InnovationminorStrategic or Co-development PartnerListed as technology development partner on company website.
  • MTP ConnectminorStrategic or Co-development PartnerMedical Technology Partner Connect organization supporting Australian medtech innovation ecosystem. Listed as partner on company website.

Scale indicators7 records

Recent moves6 records

Expansion highlights3 records

Clever Culture Systems competitors and assessment

Company assessment

Direct peers

  • Copan Diagnostics: Copan provides automated specimen processing and liquid-based microbiology workflows (WASPLab) with imaging and AI-assisted colony detection. It competes with APAS Independence in the automated microbiology lab segment.
  • Becton Dickinson (BD) - Kiestra: BD's Kiestra is the leading total laboratory automation platform for clinical microbiology, including automated plate imaging and incubation. It is the closest direct competitor to APAS Independence in automated culture plate reading for clinical microbiology labs.

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad provides quality control and microbiology products, including the Unity Real Time QC and various clinical microbiology reagents. It is an incumbent adjacent competitor for laboratory QC and microbiology workflows.
  • Beckman Coulter (Danaher): Beckman Coulter offers clinical laboratory automation and microbiology solutions through Danaher's Diagnostics platform. It is a broader incumbent in lab automation that competes for the same clinical microbiology budgets.
  • bioMérieux: bioMérieux is a global leader in in-vitro diagnostics and industrial microbiology, offering BACT/ALERT, VITEK, and laboratory automation products. It overlaps with APAS Independence across clinical microbiology and pharmaceutical QC.

Emerging players

  • Specific Diagnostics: Specific Diagnostics is a smaller emerging player offering rapid phenotypic AST with instrumented readouts. It competes with the APAS Zone Reader RUO module for AST workflow mindshare in clinical microbiology labs.
  • Accelerate Diagnostics: Accelerate Diagnostics offers the Accelerate Pheno system for rapid identification and AST directly from positive blood cultures. It is an emerging competitor in AI/automation-enabled clinical microbiology.
  • T2 Biosystems: T2 Biosystems provides T2 Magnetic Resonance-based rapid diagnostic panels for sepsis-causing pathogens. It competes for microbiology lab budgets on AI/automation-enabled rapid diagnostics.
  • Selux Diagnostics: Selux Diagnostics is developing rapid AST platforms for bloodstream and other infections. It overlaps with APAS Independence's RUO antimicrobial susceptibility testing capabilities.

Others

  • Thermo Fisher Scientific: Thermo Fisher Scientific is Clever Culture Systems' global channel partner and also offers its own microbiology and laboratory products. It is included as a strategic enabler/distributor rather than a direct plate-reader competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Clever Culture Systems social profiles

Digital presence

Clever Culture Systems compliance and trust

Trust signal

Compliance2 records

Clever Culture Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clever Culture Systems leadership team

Management profile

Number of profiles

Profiles11 records

Clever Culture Systems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clever Culture Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clever Culture Systems

What does Clever Culture Systems do?

Clever Culture Systems develops and commercializes the APAS Independence, an AI-powered laboratory instrument that automates imaging, interpretation, and reporting of microbial growth on agar culture plates for pharmaceutical and clinical microbiology laboratories. The platform combines proprietary machine learning with automated plate handling to process approximately 200 culture plates per hour, and is sold alongside a suite of specialized AI analysis modules for pharmaceutical environmental monitoring and clinical diagnostics applications.

Is Clever Culture Systems a public or private company?

Clever Culture Systems is a public company. It is classified as public and is currently operating.

When was Clever Culture Systems founded?

Clever Culture Systems was founded in 2016. It employs 11 to 50 people.

Where is Clever Culture Systems based?

Clever Culture Systems is headquartered in Bach, Switzerland, in the Europe region.

How does Clever Culture Systems make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are software/Subscription Fees, service and Maintenance and implementation and Training.

Who are Clever Culture Systems's main competitors?

Direct peers on record are Copan Diagnostics and Becton Dickinson (BD) - Kiestra. Broad incumbents are Bio-Rad Laboratories, Beckman Coulter (Danaher) and bioMérieux. Emerging players are Specific Diagnostics, Accelerate Diagnostics, T2 Biosystems and Selux Diagnostics. Thermo Fisher Scientific is listed as an others.

Does Clever Culture Systems have an API?

No public API is recorded for Clever Culture Systems.

What industry is Clever Culture Systems in?

Clever Culture Systems's product category is Laboratory Automation Instruments. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestClever Culture Systems - Company expects step-change sales increase commencing FY27Clever Culture Systems expects a step-change in sales growth for fiscal year 2027, driven by its expanding pharmaceutical client base. The company doubled its major pharmaceutical clients to eight, including Novo Nordisk and CSL, and has over 30 APAS Independence instruments installed globally. Its sales pipeline includes 180 qualified opportunities, with 100 additional instrument sales from current pharmaceutical clients.KalkineClever Culture Systems (ASX:CC5): CSL Evaluation Deal Puts This ASX MedTech in the Growth LaneClever Culture Systems (ASX:CC5), an Australian medtech company, has secured an evaluation agreement with global biotech firm CSL for its APAS (Automated Plate Assessment System), which uses imaging and AI to automate microbiology culture plate reading. The evaluation represents meaningful validation from a sophisticated pharmaceutical partner in the typically long sales cycle of laboratory technology, potentially paving the way for commercial deployment. The company, which has a deployed product with applications in both clinical diagnostics and industrial pharmaceutical quality control, aims to convert such validations into recurring revenue streams as it scales adoption.Investing.comEarnings call transcript: Clever Culture Systems Q3 2026 highlights growth strategy By Investing.comClever Culture Systems (CC5) held its Q3 2026 earnings call, reporting a cash position of AUD 2.0 million with expected inflows of at least AUD 2.6 million over the next two quarters from committed instrument sales and R&D tax incentives. The company announced sales of 2 instruments through its channel partner Thermo Fisher and expects to add at least 2 new top 20 pharmaceutical customers by end of FY 2026, while also planning an APAS Discovery Day at AstraZeneca in the UK to showcase its platform capabilities.PR NewswireClever Culture Systems Appoints Thermo Fisher Scientific as Exclusive US APAS® DistributorAustralian medical technology company LBT Innovations' 50%-owned joint venture Clever Culture Systems has signed a five-year exclusive distribution agreement with Thermo Fisher Scientific (through subsidiary Remel Inc.) for the APAS® Independence automated culture plate reader in the United States. Thermo Fisher will handle all sales, marketing, installation, maintenance, and customer support for the FDA-cleared device, which uses artificial intelligence to interpret bacterial growth on culture plates. The agreement grants access to what LBT describes as the largest global market with over 1,500 target laboratories, representing a major milestone in LBT's US commercialization strategy.